<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517540</url>
  </required_header>
  <id_info>
    <org_study_id>CLJC242A2201J</org_study_id>
    <secondary_id>2017-004208-24</secondary_id>
    <secondary_id>LJC242A2201J</secondary_id>
    <nct_id>NCT03517540</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis</brief_title>
  <acronym>TANDEM</acronym>
  <official_title>A Randomized, Double-blind, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and efficacy of a
      combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with
      nonalcoholic steatohepatitis (NASH) and liver fibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2018</start_date>
  <completion_date type="Anticipated">July 13, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Occurrence of adverse events and serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who have at least a one point improvement in fibrosis</measure>
    <time_frame>baseline to 48 Weeks</time_frame>
    <description>Efficacy of tropifexor + CVC in patients with Nonalcoholic steatohepatitis (NASH) with fibrosis stage F2/F3 as assessed by histological improvement after 48 weeks of treatment compared to monotherapies (tropifexor and CVC) compared to baseline biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with resolution of steatohepatitis</measure>
    <time_frame>baseline to 48 weeks</time_frame>
    <description>Efficacy of tropifexor + CVC in patients with Nonalcoholic steatohepatitis (NASH) with fibrosis stage F2/F3 as assessed by histological improvement after 48 weeks of treatment compared to monotherapies (tropifexor and CVC) compared to baseline biopsy</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Arm A: Tropifexor (LJN452) - Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Cenicriviroc (CVC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Tropifexor (LJN452) Dose 1 + CVC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Tropifexor Dose 2 + CVC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tropifexor (LJN452)</intervention_name>
    <description>Comparison with monotherapy and different combination doses</description>
    <arm_group_label>Arm A: Tropifexor (LJN452) - Dose 1</arm_group_label>
    <arm_group_label>Arm C: Tropifexor (LJN452) Dose 1 + CVC</arm_group_label>
    <arm_group_label>Arm D: Tropifexor Dose 2 + CVC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cenicriviroc (CVC)</intervention_name>
    <description>Comparison with monotherapy and different combination doses</description>
    <arm_group_label>Arm B: Cenicriviroc (CVC)</arm_group_label>
    <arm_group_label>Arm C: Tropifexor (LJN452) Dose 1 + CVC</arm_group_label>
    <arm_group_label>Arm D: Tropifexor Dose 2 + CVC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Written informed consent Male and female patients 18 years or older (at the time of the
        screening visit). Patients must weigh at least 50 kg (110 lb) and no more than 200 kg (440
        lb) to participate in the study.

        Able to communicate well with the investigator, to understand and comply with the
        requirements of the study.

        Adequate liver biopsy sample for evaluation by Central Reader. Presence of NASH as
        demonstrated by histologic evidence based on liver biopsy - NASH with fibrosis stage F2/F3,
        demonstrated on liver biopsy during the screening period. Alternatively, a historical
        biopsy can be used if performed within 6 months prior to screening.

        Exclusion Criteria:

        Use of other investigational drugs within 5 half-lives of enrollment or within 30 days
        whichever is longer.

        History of hypersensitivity to any of the study drugs or its excipients or to drugs of
        similar chemical classes.

        Previous exposure to elafibranor, CVC, tropifexor, obeticholic acid (OCA), LMB763 or other
        FXR agonist.

        Participated in a clinical trial and treated with any investigational product being
        evaluated for the treatment of liver fibrosis or NASH in the 6 months before screening.

        Patients taking medications prohibited by the protocol. History of treated or untreated
        malignancy of any organ system, other than localized basal cell carcinoma of the skin or
        treated cervical intraepithelial neoplasia, within the past 5 years, regardless of whether
        there is evidence of local recurrence or metastases .

        Pregnant or nursing (lactating) women. Women of child-bearing potential,9. Current or
        history of significant alcohol consumption for a period of more than 3 consecutive months
        within 1 year prior to screening (significant alcohol consumption is defined as more than
        20 g/day in females and more than 30 g/day in males, on average) and/or a score on the
        modified AUDIT questionnaire ≥ 8 Uncontrolled diabetes defined as HbA1c ≥ 9% at screening
        Clinical evidence of hepatic decompensation or severe liver impairment 15. Previous
        diagnosis of other forms of chronic liver disease:16. Calculated eGFR less than 60 mL/min
        (using the MDRD formula) History of biliary diversion History of liver transplantation or
        planned liver transplant History of inflammatory bowel disease Patients who are not
        candidates for liver biopsy Presence of cirrhosis on liver biopsy (F4 by NASH CRN System)
        or medical history Platelet count &lt; 120 ×109/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Fatty Liver Disease</keyword>
  <keyword>Liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>TAK-652</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

